Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous dose-limiting toxicity, has secured a $30 million financing to advance the development of LUT014, a topically applied gel aimed at reducing EGFRi-induced rashes, a common adverse side effect of cancer-fighting therapies. The round was led by Columbus Venture Partners and Pontifax Venture Capital, an existing investor, with Peregrine Ventures and aMoon Fund also participat...